SCHEMBL7186764

SCHEMBL7186764

COc1ccc(OC)c(C(=O)P(=O)(C(=O)c2c(Cl)cccc2Cl)c2ccccc2)c1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 1/20 0.40
TOP1 P11387 1/20 0.40
RAB9A P51151 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
FABP4 P15090 1/20 0.39
PTGS2 P35354 3/20 0.38
TUBB4A P04350 2/20 0.38
TUBB P07437 2/20 0.38
TUBA3C P0DPH7 2/20 0.38
TUBA1B P68363 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182521 0.96 CA12 (0.42) ALDH1A1KDM4EHSD17B10TOP1RAB9A
SCHEMBL7187078 0.94 ALDH1A1 (0.49) ALDH1A1KDM4EHSD17B10TOP1KMT2A
SCHEMBL7175298 0.93 TOP1 (0.40) ALDH1A1KDM4EHSD17B10TOP1RAB9A
SCHEMBL7182579 0.90 TOP1 (0.40) ALDH1A1KDM4EHSD17B10TOP1MEN1
SCHEMBL7185629 0.90 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10TOP1RAB9A
SCHEMBL7186465 0.89 CA12 (0.47) ALDH1A1CA12CA1CA2CA7
SCHEMBL7181642 0.89 CA12 (0.47) ALDH1A1CA12CA1CA2CA7
SCHEMBL7188992 0.89 CA12 (0.47) ALDH1A1KDM4ERAB9AMEN1KMT2A
SCHEMBL7175437 0.87 ALDH1A1 (0.47) ALDH1A1KDM4EHSD17B10TOP1RAB9A
SCHEMBL7189534 0.87 ALDH1A1 (0.45) ALDH1A1KDM4EHSD17B10TOP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ALDH1A1 3416/4885KDM4E 3226/4885HSD17B10 56/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ALDH1A1 3984/4885KDM4E 2651/4885HSD17B10 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.